PF-Atlas › Clinical Trials › NCT01872689

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis

Lebrikizumab · Phase 2

Registry ID

NCT01872689

Phase

Phase 2

Status

Completed

Drug / intervention

Lebrikizumab

Sponsor

Hoffmann-La Roche

Start

2013-10-13

Enrollment

505

Locations

112

About this trial

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy and as combination therapy with pirfenidone background therapy in participants with IPF. Participants will be randomized to receive either lebrikizumab or placebo subcutaneously every 4 weeks.

View NCT01872689 on ClinicalTrials.gov →

Explore related

All Lebrikizumab trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT01872689 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.